Published in J Clin Oncol on January 01, 2003
Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer (2003) 1.95
Predictive factors improving survival after gastrectomy in gastric cancer patients with peritoneal carcinomatosis. World J Surg (2010) 1.72
Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol (2008) 1.62
Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer (2006) 1.60
Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer (2011) 1.58
Giant Krukenberg tumor from a perforated gastric cancer that was successfully removed after multidisciplinary therapy: report of a case. Surg Today (2012) 1.39
Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer (2008) 1.39
Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer (2004) 1.37
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. J Natl Cancer Inst (2013) 1.28
Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer (2004) 1.27
Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer (2006) 1.21
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol (2013) 1.18
Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. Br J Cancer (2006) 1.11
Follow-up of gastric cancer: a review. Gastric Cancer (2006) 1.10
Effect of RECIST revision on classification of target lesions and overall response in advanced gastric cancer patients. Gastric Cancer (2012) 1.04
Preliminary trial of adjuvant surgery for advanced gastric cancer. Oncol Lett (2010) 1.03
Treatment options in patients with metastatic gastric cancer: current status and future perspectives. World J Gastroenterol (2014) 1.02
Recent advances in chemotherapy for advanced gastric cancer in Japan. Surg Today (2010) 1.00
Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine. World J Gastroenterol (2006) 0.96
Chemotherapy for advanced gastric cancer: slow but further progress. Cancer Res Treat (2005) 0.95
Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma. Br J Cancer (2006) 0.94
Chemotherapy for metastatic disease: review from JCOG trials. Int J Clin Oncol (2008) 0.93
Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer. Br J Cancer (2004) 0.93
Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts. Br J Cancer (2011) 0.92
Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Cancer Sci (2014) 0.92
Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer. Br J Cancer (2006) 0.92
Combination chemotherapy with paclitaxel, cisplatin and fluorouracil for patients with advanced and metastatic gastric or esophagogastric junction adenocarcinoma: a multicenter prospective study. Chin J Cancer Res (2012) 0.91
Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma. Br J Cancer (2008) 0.90
Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers. Gastrointest Cancer Res (2008) 0.90
Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer. Br J Cancer (2013) 0.90
Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey. Gastric Cancer (2003) 0.90
Chemotherapy for metastatic gastric cancer in Japan. Int J Clin Oncol (2008) 0.90
A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer. Gastric Cancer (2012) 0.90
Phase II study of weekly paclitaxel by one-hour infusion for advanced gastric cancer. Surg Today (2008) 0.88
Systemic therapy for advanced gastric cancer: a clinical practice guideline. Curr Oncol (2011) 0.87
Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis. World J Surg Oncol (2010) 0.87
Chemotherapy for advanced gastric cancer: review of global and Japanese status. Gastrointest Cancer Res (2007) 0.86
Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912. Gastric Cancer (2013) 0.85
An individualized prognostic signature for gastric cancer patients treated with 5-Fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups. Oncotarget (2016) 0.85
Outcomes in elderly patients treated with a single-agent or combination regimen as first-line chemotherapy for recurrent or metastatic gastric cancer. Gastric Cancer (2014) 0.85
Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study). Int J Clin Oncol (2008) 0.84
Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials. Invest New Drugs (2011) 0.83
Significant prognostic factors in patients with Stage IV gastric cancer with special reference to the curability of surgery. Surg Today (2012) 0.83
S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis. PLoS One (2013) 0.83
Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer. Gastric Cancer (2011) 0.82
Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer. Gastric Cancer (2010) 0.82
Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies. Onco Targets Ther (2011) 0.82
Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients. World J Gastrointest Oncol (2009) 0.81
Chemotherapy for patients with advanced gastric cancer with performance status 2. Gastrointest Cancer Res (2009) 0.81
Second-line chemotherapy for advanced gastric cancer in Korea. Gastric Cancer (2012) 0.81
Advanced gastric cancer: an update and future directions. Gastrointest Cancer Res (2008) 0.81
Efficacy of S-1 plus cisplatin combination chemotherapy in patients with HER2-positive advanced gastric cancer. Int J Clin Oncol (2013) 0.81
Chemotherapy for gastric cancer in Japan. Int J Clin Oncol (2008) 0.80
Irinotecan-involved regimens for advanced gastric cancer: a pooled-analysis of clinical trials. World J Gastroenterol (2010) 0.80
Phase II clinical trial of advanced and metastatic gastric cancer based on continuous infusion of 5-fluorouracil combined with epirubicin and oxaliplatin. J Cancer Res Clin Oncol (2008) 0.80
A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. Cancer Chemother Pharmacol (2014) 0.80
Preliminary trial of surgery after chemotherapy for advanced gastric cancer with peritoneal dissemination. Oncol Lett (2011) 0.80
A patient with gastric cancer and liver metastases successfully treated with combination chemotherapy including S-1. Int J Clin Oncol (2007) 0.80
Irinotecan is inactive as a first-line treatment, but plays an important part in gastric cancer treatment. Gastric Cancer (2011) 0.79
Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas. Invest New Drugs (2012) 0.79
Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan. World J Gastroenterol (2014) 0.79
Global chemotherapy development for gastric cancer. Gastric Cancer (2016) 0.79
Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer. J Cancer Res Clin Oncol (2010) 0.79
A feasibility study of outpatient chemotherapy with S-1 + cisplatin in patients with advanced gastric cancer. Gastric Cancer (2012) 0.78
A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer. Gastric Cancer (2016) 0.78
Recent advances in chemotherapy for advanced gastric cancer. World J Gastrointest Oncol (2010) 0.78
The impact of hemoglobin level and transfusion on the outcomes of chemotherapy in gastric cancer patients. Int J Clin Exp Med (2015) 0.78
Chemotherapy in metastatic gastric cancer: population-based perceptions and practice patterns of medical oncologists. Br J Cancer (2004) 0.78
Standard First-Line Chemotherapy for Metastatic Gastric Cancer in Japan Has Met the Global Standard: Evidence From Recent Phase III Trials. Gastrointest Cancer Res (2009) 0.78
Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination. Invest New Drugs (2010) 0.78
Second-line chemotherapy for gastric cancer: a new issue lies ahead in global trials. Gastric Cancer (2011) 0.78
Refining docetaxel-containing therapy for gastric cancer. Gastrointest Cancer Res (2011) 0.78
Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer. Oncotarget (2016) 0.78
The efficacy of gastrectomy for large gastric cancer. Int J Clin Oncol (2006) 0.77
Recent Developments in Cytotoxic Therapy for Advanced Gastric or Gastroesophageal Carcinoma: The Phase III Trials. Gastrointest Cancer Res (2007) 0.77
Phase II study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer. World J Gastroenterol (2006) 0.77
Diverse eastern and Western approaches to the management of gastric cancer. Gastrointest Cancer Res (2007) 0.77
Randomized, multicenter, phase III trial of heptaplatin 1-hour infusion and 5-fluorouracil combination chemotherapy comparing with cisplatin and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer. Cancer Res Treat (2009) 0.77
Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy. J Gastroenterol (2007) 0.77
Comparison of advanced adenocarcinomas of esophagogastric junction and distal stomach in Japanese patients. Gastric Cancer (2013) 0.77
Clinical outcomes of TS-1 chemotherapy for advanced and recurrent gastric cancer. J Korean Surg Soc (2011) 0.76
First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer. Gastric Cancer (2011) 0.76
S-1 plus intravenous and intraperitoneal Paclitaxel for gastric cancer with peritoneal metastasis. Gastrointest Cancer Res (2012) 0.76
Chemotherapy in Elderly Patients with Gastric Cancer. J Cancer (2016) 0.76
Review of docetaxel in the treatment of gastric cancer. Ther Clin Risk Manag (2008) 0.76
Irinotecan plus mitomycin C as second-line chemotherapy for advanced gastric cancer resistant to fluoropyrimidine and Cisplatin: a retrospective study. Gastroenterol Res Pract (2012) 0.75
A case of advanced gastric cancer achieved a pathological complete response by chemotherapy. Surg Case Rep (2017) 0.75
Inter-institutional heterogeneity in outcomes of chemotherapy for metastatic gastric cancer: correlative study in the JCOG9912 phase III trial. ESMO Open (2016) 0.75
Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer. BMC Cancer (2005) 0.75
A pilot study of cisplatin, irinotecan, leucovorin and 5-fluorouracil (PILF) combination chemotherapy for advanced gastric cancer. Cancer Res Treat (2006) 0.75
Programmed chemotherapy for patients with metastatic unresectable gastric cancer. PLoS One (2012) 0.75
Global perspectives on chemotherapy for patients with gastric carcinoma: a roundtable discussion. Gastrointest Cancer Res (2007) 0.75
Eight-year survival after advanced gastric cancer treated with S-1 followed by surgery. World J Gastroenterol (2010) 0.75
Efficacy of paclitaxel-based doublet regimens combining with intraperitoneal chemotherapy for advanced gastric cancer with peritoneal metastasis. Int J Clin Exp Med (2015) 0.75
Complications in advanced or recurrent gastric cancer patients with peritoneal metastasis during and after palliative systemic chemotherapy. Mol Clin Oncol (2015) 0.75
Anti-Gastrins Antiserum Combined with Lowered Dosage Cytotoxic Drugs to Inhibit the Growth of Human Gastric Cancer SGC7901 Cells in Nude Mice. J Cancer (2015) 0.75
The current situation for gastric cancer in Chile. Ecancermedicalscience (2016) 0.75
A phase II trial of paclitaxel, 5-fluorouracil (5-FU) and cisplatin in patients with metastatic or recurrent gastric cancer. Cancer Res Treat (2008) 0.75
Direct liver invasion from a gastric adenocarcinoma as an initial presentation of extranodal tumor spread. Case Rep Med (2012) 0.75
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol (2009) 21.94
D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med (2008) 9.00
Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med (2005) 8.25
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med (2002) 7.59
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol (2011) 5.39
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol (2009) 5.19
Appearance of enhanced tissue features in narrow-band endoscopic imaging. J Biomed Opt (2004) 5.16
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol (2005) 5.10
Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. J Clin Oncol (2004) 4.31
A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol (2011) 4.22
Endoscopic submucosal dissection of early esophageal cancer. Clin Gastroenterol Hepatol (2005) 4.20
Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med (2013) 3.95
A prospective, multicenter study of 1111 colorectal endoscopic submucosal dissections (with video). Gastrointest Endosc (2010) 3.53
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol (2013) 3.26
Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med (2015) 3.09
A multicenter retrospective study of endoscopic resection for early gastric cancer. Gastric Cancer (2006) 2.98
Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet (2008) 2.89
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol (2002) 2.89
Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204. J Clin Oncol (2003) 2.86
Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res (2011) 2.81
A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201). J Thorac Oncol (2011) 2.78
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol (2010) 2.73
Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol (2006) 2.73
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol (2015) 2.70
Squamous cell carcinoma in situ at oropharyngeal and hypopharyngeal mucosal sites. Cancer (2004) 2.67
Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version. Int J Clin Oncol (2008) 2.65
The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol (2008) 2.56
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol (2013) 2.45
Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol (2003) 2.31
Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol (2009) 2.31
Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol (2003) 2.27
Two essential but distinct functions of the mammalian abasic endonuclease. Proc Natl Acad Sci U S A (2005) 2.26
Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Gynecol Oncol (2009) 2.16
UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther (2004) 2.14
Nonpolypoid neoplastic lesions of the colorectal mucosa. Gastrointest Endosc (2008) 2.09
Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol (2012) 2.03
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics (2007) 2.01
A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol (2009) 1.99
Efficacy of clinical pathway for the management of mucosal gastric carcinoma treated with endoscopic submucosal dissection using an insulated-tip diathermic knife. Intern Med (2004) 1.93
Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep (2006) 1.91
Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol (2006) 1.88
Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial. Jpn J Clin Oncol (2006) 1.88
Demographics, lifestyles, health characteristics, and dietary intake among dietary supplement users in Japan. Int J Epidemiol (2003) 1.85
Meshed capillary vessels by use of narrow-band imaging for differential diagnosis of small colorectal polyps. Gastrointest Endosc (2008) 1.84
Central projection of unmyelinated (C) primary afferent fibers from gastrocnemius muscle in the guinea pig. J Comp Neurol (2003) 1.83
Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol (2004) 1.83
Esophageal stenosis after endoscopic mucosal resection of superficial esophageal lesions. Gastrointest Endosc (2003) 1.82
Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG 0703). Gastric Cancer (2010) 1.81
Genetic polymorphisms of alcohol and aldehyde dehydrogenases and glutathione S-transferase M1 and drinking, smoking, and diet in Japanese men with esophageal squamous cell carcinoma. Carcinogenesis (2002) 1.81
VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol (2007) 1.79
Promise of definitive chemoradiotherapy for esophageal cancer balanced with late radiation toxicity: an old but new issue. J Gastroenterol (2006) 1.75
Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys (2010) 1.71
Photodynamic therapy as salvage treatment for local failures after definitive chemoradiotherapy for esophageal cancer. Gastrointest Endosc (2005) 1.71
A new technique for endoscopic mucosal resection with an insulated-tip electrosurgical knife improves the completeness of resection of intramucosal gastric neoplasms. Gastrointest Endosc (2002) 1.70
Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol (2010) 1.69
Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol (2005) 1.64
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol (2004) 1.64
Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci (2010) 1.62
Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer (2006) 1.60
A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol (2007) 1.59
Menopause, but not age, is an independent risk factor for fasting plasma glucose levels in nondiabetic women. Menopause (2007) 1.59
Daily total physical activity level and premature death in men and women: results from a large-scale population-based cohort study in Japan (JPHC study). Ann Epidemiol (2008) 1.58
CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res (2005) 1.57
Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer. Gastrointest Endosc (2002) 1.55
Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01). Jpn J Clin Oncol (2008) 1.55
EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol (2008) 1.50
Measurement of temporal changes in vocal tract area function from 3D cine-MRI data. J Acoust Soc Am (2006) 1.48
Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma: Japan clinical oncology group study JCOG 0110-MF. Jpn J Clin Oncol (2002) 1.46
Cholinergic urticaria, a new pathogenic concept: hypohidrosis due to interference with the delivery of sweat to the skin surface. Dermatology (2002) 1.45
Characteristics of the increase in plasma brain natriuretic peptide level in left ventricular systolic dysfunction, associated with muscular dystrophy in comparison with idiopathic dilated cardiomyopathy. Neuromuscul Disord (2004) 1.45
Seronegative alpha-fetoprotein-producing early gastric cancer treated with endoscopic mucosal resection and additional surgery. Intern Med (2004) 1.45
An Asian variant of intravascular lymphoma diagnosed through splenectomy. Intern Med (2002) 1.45
S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol (2008) 1.44
Impaired efficacy of cough in patients with Parkinson disease. Chest (2003) 1.44
Cigarette smoking and subsequent risk of lung cancer by histologic type in middle-aged Japanese men and women: the JPHC study. Int J Cancer (2002) 1.43
Iatrogenic perforation associated with therapeutic colonoscopy: a multicenter study in Japan. J Gastroenterol Hepatol (2007) 1.42
A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol (2007) 1.41
The Influence of handling censored data on estimating progression-free survival in cancer clinical trials (JCOG9913-A). Jpn J Clin Oncol (2002) 1.40
Primary signet-ring cell carcinoma of the colon at early stage: a case report and a review of the literature. World J Gastroenterol (2006) 1.38
Phase I/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI. J Vasc Interv Radiol (2012) 1.38